Hussain A - Search Results

1

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.

Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Hussain A, et al. Ann Oncol. 2009 Mar;20(3):492-7. doi: 10.1093/annonc/mdn665. Epub 2008 Dec 15. Ann Oncol. 2009. PMID: 19087985 Free article. Clinical Trial.

2

Management of advanced/metastatic prostate cancer: 2000 update.

Hussain A, Dawson N. Hussain A, et al. Oncology (Williston Park). 2000 Dec;14(12):1677-88; discussion 1688, 1691-4. Oncology (Williston Park). 2000. PMID: 11204373 Free article. Review.

3

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T. Hussain A, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):22-31. doi: 10.1016/s0093-7754(01)90151-4. Semin Oncol. 2001. PMID: 11685725 Clinical Trial.

4

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.

Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A. Dawson NA, et al. Among authors: hussain a. Clin Cancer Res. 2004 Dec 1;10(23):7812-9. doi: 10.1158/1078-0432.CCR-04-0310. Clin Cancer Res. 2004. PMID: 15585612 Clinical Trial.

5

Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.

Hussain A, Dawson N, Amin P, Engstrom C, Dorsey B, Siegel E, Guo C. Hussain A, et al. J Clin Oncol. 2005 Apr 20;23(12):2789-96. doi: 10.1200/JCO.2005.07.152. J Clin Oncol. 2005. PMID: 15837994 Clinical Trial.

6

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Smith MR, et al. Among authors: hussain a. J Clin Oncol. 2005 May 1;23(13):2918-25. doi: 10.1200/JCO.2005.01.529. J Clin Oncol. 2005. PMID: 15860850 Clinical Trial.

7

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.

Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A. Tang Y, et al. Among authors: hussain a. Clin Cancer Res. 2006 Jan 1;12(1):169-74. doi: 10.1158/1078-0432.CCR-05-1388. Clin Cancer Res. 2006. PMID: 16397039

8

Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.

Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. Tang Y, et al. Among authors: hussain a. Clin Cancer Res. 2008 May 15;14(10):2936-43. doi: 10.1158/1078-0432.CCR-07-4925. Clin Cancer Res. 2008. PMID: 18483360

9

Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.

Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, Alexander RB. Kouiavskaia DV, et al. Among authors: hussain a. J Immunother. 2009 Jul-Aug;32(6):655-66. doi: 10.1097/CJI.0b013e3181a80e0d. J Immunother. 2009. PMID: 19483644 Free PMC article. Clinical Trial.

10

The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice.

Tang Y, Wang L, Goloubeva O, Khan MA, Lee D, Hussain A. Tang Y, et al. Among authors: hussain a. Prostate. 2009 Dec 1;69(16):1763-73. doi: 10.1002/pros.21026. Prostate. 2009. PMID: 19691128

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,640 results

Search Page

Filters